Short answer · Medically reviewed summary · Last updated: 2026-05-08
Best Vitelliform Macular Dystrophy is a genetic eye disorder caused by mutations in the BEST1 gene, which leads to the abnormal accumulation of yellowish, egg-yolk-like material under the retina. This condition is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene from one parent is sufficient to cause the disease. What causes Best Vitelliform Macular Dystrophy? The primary cause of Best Vitelliform Macular Dystrophy is a mutation in the BEST1 gene.
Best Vitelliform Macular Dystrophy is a genetic eye disorder caused by mutations in the BEST1 gene, which leads to the abnormal accumulation of yellowish, egg-yolk-like material under the retina. This condition is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene from one parent is sufficient to cause the disease.
The primary cause of Best Vitelliform Macular Dystrophy is a mutation in the BEST1 gene. This gene provides instructions for creating a protein called bestrophin-1, which functions as a channel for chloride ions in the retinal pigment epithelium (RPE). Think of the RPE as a support layer for the light-sensing cells in your eye; when the bestrophin-1 channel malfunctions, the RPE cannot properly manage the fluid and waste products behind the retina, leading to the characteristic "vitelliform" (egg-yolk) lesions.
Yes, Best Vitelliform Macular Dystrophy is an inherited condition. It follows an autosomal dominant inheritance pattern, which means if one parent carries the mutation, there is a 50% chance they will pass it to each child. While the genetic cause is well-established, there is significant variability in how the disease manifests, even among family members with the exact same mutation.
While the underlying cause is genetic, the severity and age of onset for Best Vitelliform Macular Dystrophy can be influenced by several factors:
Current research is focused on gene therapy to correct the BEST1 mutation and stem cell therapies to replace damaged RPE cells. Scientists at DiseaseMaps.org and beyond are actively studying why the accumulation of lipofuscin occurs in some patients but not others, aiming to unlock new ways to stabilize vision.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.